↓ Skip to main content

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Overview of attention for article published in Journal of Hematology & Oncology, March 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

policy
1 policy source
twitter
5 tweeters

Citations

dimensions_citation
131 Dimensions

Readers on

mendeley
105 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Published in
Journal of Hematology & Oncology, March 2014
DOI 10.1186/1756-8722-7-24
Pubmed ID
Authors

Nancy L Bartlett, Robert Chen, Michelle A Fanale, Pauline Brice, Ajay Gopal, Scott E Smith, Ranjana Advani, Jeffrey V Matous, Radhakrishnan Ramchandren, Joseph D Rosenblatt, Dirk Huebner, Pamela Levine, Laurie Grove, Andres Forero-Torres

Abstract

Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab vedotin monotherapy was investigated in patients with CD30-positive Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (ALCL) who relapsed after achieving complete or partial remission (CR or PR) with initial brentuximab vedotin therapy in a previous study (ClinicalTrials.gov NCT00947856).

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 105 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Japan 1 <1%
India 1 <1%
Peru 1 <1%
Unknown 101 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 26 25%
Other 20 19%
Student > Master 8 8%
Professor 6 6%
Student > Bachelor 6 6%
Other 19 18%
Unknown 20 19%
Readers by discipline Count As %
Medicine and Dentistry 48 46%
Biochemistry, Genetics and Molecular Biology 6 6%
Nursing and Health Professions 5 5%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Agricultural and Biological Sciences 4 4%
Other 14 13%
Unknown 23 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2018.
All research outputs
#3,413,714
of 17,359,532 outputs
Outputs from Journal of Hematology & Oncology
#173
of 860 outputs
Outputs of similar age
#60,151
of 313,546 outputs
Outputs of similar age from Journal of Hematology & Oncology
#9
of 51 outputs
Altmetric has tracked 17,359,532 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 860 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 313,546 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.